Julie KANTER WASHKO
University of Alabama Birmingham
Thursday, June 16th 17:55 - 18:00 UTC+2
Thursday, June 16th 17:55 - 18:35 UTC+2
Looking ahead: how will novel therapies change our approach to clinical management?
Thursday, June 16th 18:18 - 18:28 UTC+2
GRNDaD and CoUSIn: Investigator-initiated collaborations to improve care in Sickle Cell Disease
Thursday, June 16th 19:35 - 19:38 UTC+2
Understanding gene therapy for Sickle Cell Disease
Saturday, June 18th 08:30 - 08:50 UTC+2
Julie Kanter, MD, is the Director of the Adult Sickle Cell Program at the University of Alabama at Birmingham. She is a lifespan hematologist specializing in SCD. Her research is focused on improving access to care through dissemination and implementation and in the development of novel therapies to improve SCD outcomes. She works closely with national partners on advocacy and research and is currently the president of the National Alliance of Sickle Cell Centers. Dr. Kanter has received NHLBI, HRSA and CDC funding hoping to improve quality of care and access to care for affected individuals